… in specific patient subsets. In addition, we discuss the clinical efficacy and safety of bortezomib.
… and pharmacodynamic profiles of bortezomib in adult patients with cancer with various …

… bortezomib in solid tumors used as a daily subcutaneous regimen. Previous regimens showed
only modest activity in solid tumors … contribution of the different micro-environment of liver …

The usefulness of pharmacokinetics of bortezomib for multiple myeloma (MM) with respect
to the maximum response to bortezomib and bortezomib-induced peripheral neuropathy (…

… The pharmacokinetics of bortezomib has not been clarified in multiple myeloma patients. …
and combination regimens investigated with all the different agents is beyond the scope of this …

Background This study aims to compare the efficacy and adverse reactions of bortezomib
for treating newly diagnosed multiple myeloma (MM) through two different administration …

… 8, and cycle 1, day 15 at pre-dose, and various intervals post-dose up to 48 h. In the dose …
This study summarizes key analyses of panobinostat pharmacokinetics that will be useful in …

… bortezomib in humans has not been fully elucidated, the pharmacokinetics of bortezomib are
not altered by varying … clearance of bortezomib (8). In vitro studies have demonstrated that …

… Lastly, a phase I study of BTZ in various degrees of hepatic impairment showed that AUC last
was … Bortezomib was first studied in phase I trials of patients with advanced solid tumor and …

… , varying grades of renal impairment did not alter bortezomib … of the pharmacokinetics of
bortezomib in patients less than 2 … to simulations based solely on adult pharmacokinetic data. …

… Provocative results from a French study have recently been released looking at two
different bortezomib-containing regimens as induction chemotherapy (four courses) prior to …